Kantoff Aaron
- SEC CIK
- 0001862734
No open-market purchases or sales filed in the past year.
Current role at each company
- AVTX Avalo Therapeutics, Inc.Directoras of Jun 4, 2026
- TRML Tourmaline Bio, Inc.Directoras of Oct 28, 2025
- CNTA Centessa Pharmaceuticals plcDirectoras of Nov 18, 2021
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists Kantoff Aaron as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
TRML Tourmaline Bio, Inc.
Director1 trade
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 26, 2023 (view filing) | Oct 24 | 2 days | Kantoff AaronDirector | PPurchase | +7.50K | $11.86 | +$89.0K | +19.8%45.4K after |
CNTA Centessa Pharmaceuticals plc
Director1 trade
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 18, 2021 (view filing) | Nov 18 | Same day | Kantoff AaronDirector | PPurchase | +10.0K | $11.99 | +$119.9K | +20.0%60.0K after |